Time trends for HIV-1 antiretroviral resistance among antiretroviral- experienced and naive pregnant women in New York City during 1991 to early 2001

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 3, 2007, Pages 329-335

  Welles, Seth L ^a   Bauer, Greta R ^b   LaRussa, Philip S ^c,d   Colgrove, Robert C ^e   Pitt, Jane ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d Women and Infants Transmission Study ^*  (Puerto Rico)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiretroviral therapy drug naive and antiretroviral therapy drug experienced pregnant women; HIV 1 antiretroviral resistance; Time trends of antiretroviral therapy resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NONHUMAN; PREGNANCY; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES; VIRUS GENE; VIRUS ISOLATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; NEW YORK CITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 33847309519     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802f1296     Document Type: Article

References (28)

1. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis. 1998;177:557-564.
2. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis. 1999;179:705-708.
3. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002;186:181-188.
4. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis. 2001;184:1120-1126.
5. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. The Women and Infants Transmission Study Group. AIDS. 2000;14:263-271.
6. Shah SS, Crane M, Monaghan K, et al. Genotypic resistance testing in HIV-infected pregnant women in an urban setting. Int J STD AIDS. 2004;15:384-387.
7. Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS. 2004;18:1571-1577.
8. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17:2635-2643.
9. Turner D, Brenner B, Routy JP, et al. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37:1627-1631.
10. Hollinger FB, Bremer JW, Myers LE, et al. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol. 1992;30:1787-1794.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51-57.
12. Pellegrin I, Segondy M, Garrigue I, et al. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy. J Acquir Immune Defic Syndr. 2000;25:465-466.
13. Coakley E, Gillis J, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS. 2000;14 (Suppl):F9-F15.
14. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis. 2003;188:1433-1443.
15. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846.
16. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis. 2005;191:2046-2052.
17. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
18. Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5:344-351.
19. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2004;20:355-364.
20. Juenther SN, Williamson C, Ristig MB, et al. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr. 2003;32:153-156.
21. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-2180.
22. Bardeguez AD, Shapiro DE, Mofenson LM, et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr. 2003;32:170-181.
23. Frenkel LM, Wagner LE II, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20:1321-1326.
24. Servais J, Lambert C, Karita E, et al. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. AIDS Res Hum Retroviruses. 2004;20:279-283.
25. Larbalestier N, Mullen J, O'Shea S, et al. Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS. 2003;17:2665-2667.
26. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093.
27. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
28. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006;41:439-446.